Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study.

Trial Profile

Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Deleobuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2012 Results will be presented at 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) according to a Boehringer Ingelheim media release.
    • 05 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2010 Tolerability and efficacy results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top